Clinical Trials Directory

Trials / Completed

CompletedNCT05177887

Traumacel PULVIS and Traumacel ENDO Applicator in the Post-market Surveillance Phase

Multicentric, Prospective Clinical Study of Traumacel PULVIS Haemostatic Powder Application With or Without the Use of Traumacel ENDO Applicator in the Post-market Surveillance Phase

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
Bioster, a.s. · Industry
Sex
All
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

Traumacel PULVIS is a sterile absorbable haemostatic plant polysaccharide powder made of the oxidized cellulose. Traumacel PULVIS is designed to stop capillary bleeding as well as to prevent bleeding in the early post-operative stage, for example to stop capillary bleeding from resection areas of parenchymatous organs, muscles, to stop bleeding after endoscopy, mainly rectoscopic, procedures. The broadness of application allows for use in procedures performed in the standard way as well as endoscopically. Traumacel ENDO Applicator is a single use, flexible, manual apparatus designed to deliver the absorbable haemostatic powder Traumacel PULVIS. The main objective of this clinical study is to confirm the safety and efficacy of the medical device Traumacel PULVIS and Traumacel ENDO Applicator when used in accordance with their intended purpose. The partial objectives are: to identify potential incompatibilities of Traumacel ENDO Applicator with other surgical instruments, in particular with different types of trocar cannulas; for both devices (Traumacel ENDO Applicator and Traumacel PULVIS) the identification and analysis of potential emerging risks; confirmation of the acceptability of the benefit-risk ratio; identification of any systematic misuse of the device or off-label use of the device in order to verify the correctness of its intended purpose.

Conditions

Interventions

TypeNameDescription
DEVICETraumacel PULVIS, Traumacel ENDO ApplicatorHaemostatic plant polysaccharide powder made of the oxidized cellulose with flexible applicator (38 cm).

Timeline

Start date
2022-02-01
Primary completion
2023-02-01
Completion
2023-02-01
First posted
2022-01-05
Last updated
2023-07-28

Locations

1 site across 1 country: Czechia

Source: ClinicalTrials.gov record NCT05177887. Inclusion in this directory is not an endorsement.